Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis.

IF 5.1 2区 医学 Q1 RHEUMATOLOGY
Antonio Tonutti, Francesca Motta, Natasa Isailovic, Angela Ceribelli, Rita Ragusa, Emanuele Nappi, Stefanos Bonovas, Carlo Selmi, Maria De Santis
{"title":"Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis.","authors":"Antonio Tonutti, Francesca Motta, Natasa Isailovic, Angela Ceribelli, Rita Ragusa, Emanuele Nappi, Stefanos Bonovas, Carlo Selmi, Maria De Santis","doi":"10.1136/rmdopen-2024-004492","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Systemic sclerosis (SSc) is associated with an increased risk of cancer. We aimed to assess the prevalence of cancer in our cohort and to explore possible associations with clinical, immunological and treatment characteristics.</p><p><strong>Methods: </strong>Our retrospective monocentric cohort study of patients with SSc recorded prevalent and incident cases of malignancy, including those diagnosed within 3 years of the SSc onset (defined as cancer-associated scleroderma) and sought associations with the clinical characteristics and the serum autoantibody profiling performed using RNA and protein immunoprecipitation, Western-blot, immunoblot and ELISA at the time of SSc diagnosis, prior to any specific treatment.</p><p><strong>Results: </strong>Among 290 patients with SSc, the overall prevalence of cancer was 20%, with 8% of cases being cancer-associated scleroderma. Both conditions were more frequent in elderly patients and in patients with positive anti-Ro52 or anti-U3-RNP. Cancer-associated scleroderma was significantly more prevalent among patients negative for both anti-centromere (ACA) and anti-topoisomerase-1 (TOPO1) antibodies, especially in the case of diffuse SSc. Immunosuppressants were not significantly associated with cancer. Patients triple negative for ACA, TOPO1 and anti-RNA polymerase III antibodies had a significantly higher risk of breast cancer.</p><p><strong>Conclusions: </strong>Cancer surveillance should be particularly careful in patients with diffuse SSc, increased age at disease onset and without classical SSc-related autoantibodies.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"10 3","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418480/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"RMD Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/rmdopen-2024-004492","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Systemic sclerosis (SSc) is associated with an increased risk of cancer. We aimed to assess the prevalence of cancer in our cohort and to explore possible associations with clinical, immunological and treatment characteristics.

Methods: Our retrospective monocentric cohort study of patients with SSc recorded prevalent and incident cases of malignancy, including those diagnosed within 3 years of the SSc onset (defined as cancer-associated scleroderma) and sought associations with the clinical characteristics and the serum autoantibody profiling performed using RNA and protein immunoprecipitation, Western-blot, immunoblot and ELISA at the time of SSc diagnosis, prior to any specific treatment.

Results: Among 290 patients with SSc, the overall prevalence of cancer was 20%, with 8% of cases being cancer-associated scleroderma. Both conditions were more frequent in elderly patients and in patients with positive anti-Ro52 or anti-U3-RNP. Cancer-associated scleroderma was significantly more prevalent among patients negative for both anti-centromere (ACA) and anti-topoisomerase-1 (TOPO1) antibodies, especially in the case of diffuse SSc. Immunosuppressants were not significantly associated with cancer. Patients triple negative for ACA, TOPO1 and anti-RNA polymerase III antibodies had a significantly higher risk of breast cancer.

Conclusions: Cancer surveillance should be particularly careful in patients with diffuse SSc, increased age at disease onset and without classical SSc-related autoantibodies.

自身抗体、皮肤亚群和免疫抑制剂是导致系统性硬化症患者患癌风险的原因。
目的:系统性硬化症(SSc)与癌症风险增加有关。我们的目的是评估队列中的癌症发病率,并探讨可能与临床、免疫学和治疗特点存在的关联:我们对SSc患者进行了回顾性单中心队列研究,记录了恶性肿瘤的发病率和偶发病例,包括在SSc发病后3年内确诊的病例(定义为癌症相关硬皮病),并寻求与SSc确诊时(在接受任何特定治疗之前)的临床特征、使用RNA和蛋白质免疫沉淀、Western-blot、免疫印迹和ELISA进行的血清自身抗体分析之间的关联:在290名SSc患者中,癌症的总发病率为20%,其中8%的病例为癌症相关硬皮病。这两种情况在老年患者和抗Ro52或抗U3-RNP阳性的患者中更为常见。在抗中心粒(ACA)和抗拓扑异构酶-1(TOPO1)抗体均为阴性的患者中,癌症相关硬皮病的发病率明显更高,尤其是在弥漫性SSc患者中。免疫抑制剂与癌症的关系不大。ACA、TOPO1和抗RNA聚合酶III抗体三阴性的患者罹患乳腺癌的风险明显更高:对于弥漫性SSc患者、发病年龄增大且无典型SSc相关自身抗体的患者,应特别注意癌症监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
RMD Open
RMD Open RHEUMATOLOGY-
CiteScore
7.30
自引率
6.50%
发文量
205
审稿时长
14 weeks
期刊介绍: RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信